Scancell gears up for summer data readouts
Last updated: 09:30 25 Jun 2025 EDT, First published: 09:18 25 Jun 2025 EDT
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has some big dates on the calendar. July will bring results from the first three groups of its phase II SCOPE trial for advanced melanoma, and it's already started dosing patients in the final group.
Broker Panmure Liberum, which has a 'buy' rating on the shares, said the early signs from Cohort 4 are positive.
Eight patients have received the treatment with no major side effects reported. This part of the trial is a little different; it's using an intradermal injection and a faster dosing schedule. Results should land before the end of next year.
The SCOPE study is testing Scancell's SCIB1 cancer vaccine alongside checkpoint inhibitors.
To explain what happens next, the company is hosting a call on Wednesday, led by chief medical officer Dr Nermeen Varawalla. According to Panmure, the aim is to work out how this data will guide the next steps in development.
There are also updates on the horizon for Scancell's other cancer vaccine platform, Modi-1. Interim results from a kidney cancer group are expected in the third quarter, with more data from head and neck cancer patients due later in the year.
Separately, Scancell plans to set up a new subsidiary called GlyMab Therapeutics to house its GlyMab antibody technology.
Panmure said this should give the company more flexibility when it comes to licensing deals and funding.
Two GlyMab assets are already partnered with Danish biotech Genmab, but there are others still in early stages.
Panmure sees this spin-out as a smart move. "The establishment of GlyMab Therapeutics should enable the company to explore different partnering strategies, while preserving the option to continue internal development," it said.
